Clinical impact of capsule endoscopy on patients with suspected small bowel bleeding: Experience at a highly specialized hospital in Colombia.

INTRODUCTION AND AIMS: Capsule endoscopy is part of the diagnostic approach to patients with suspected small bowel bleeding and data on its clinical impact are still limited in developing countries. The primary aim of the present study was to determine its impact on subsequent diagnostic and therapeutic decisions. MATERIAL AND METHODS: A retrospective study was conducted that included all the patients that underwent capsule endoscopy with the PillCam™ SB 3 Capsule system due to suspected small bowel bleeding treated at the Hospital Universitario Fundación Valle del Lili between January 2011 and December 2020. RESULTS: A total of 158 patients met the inclusion criteria. Mean patient age was 63 years (interquartile range [IQR], 52-74), 53.6% of the patients were women, and high blood pressure was the most frequent comorbidity (43.7%). The main indication was overt bleeding (58.2%). Of all the capsule endoscopies carried out, 63.9% showed lesions that were potentially responsible for bleeding. Medical or surgical treatment was indicated in 63.3% of the case total. Rebleeding at 6 months occurred in 15 patients and there were 2 deaths due to gastrointestinal bleeding at 6 months. CONCLUSIONS: Capsule endoscopy has a high impact on patients with suspected small bowel bleeding, with respect to clinical decision-making, as well as rebleeding, hospitalization, and mortality outcomes. The positivity rate of lesions potentially responsible for bleeding was similar to that reported in developed countries.

Biomaterials Used for Periodontal Disease Treatment: Focusing on Immunomodulatory Properties.

The growing use of biomaterials with different therapeutic purposes increases the need for their physiological understanding as well as to seek its integration with the human body. Chronic inflammatory local pathologies, generally associated with infectious or autoimmunity processes, have been a current therapeutic target due to the difficulty in their treatment. The recent development of biomaterials with immunomodulatory capacity would then become one of the possible strategies for their management in local pathologies, by intervening in situ, without generating alterations in the systemic immune response. The treatment of periodontal disease as an inflammatory entity has involved the use of different approaches and biomaterials. There is no conclusive, high evidence about the use of these biomaterials in the regeneration of periodontitis sequelae, so the profession keeps looking for other different strategies. The use of biomaterials with immunomodulatory properties could be one, with a promising future. This review of the literature summarizes the scientific evidence about biomaterials used in the treatment of periodontal disease.

A facile synthesis of CuBi2O4 hierarchical dumbbell-shaped nanorod cluster: a promising photocatalyst for the degradation of caffeic acid.

The present study reports on the synthesis of Cu-bismuth oxide (CuBi2O4)-based nanorods by using a simple co-precipitation method for the photocatalytic degradation of caffeic acid (CA). The incorporation of Cu metal ions during the synthesis of CuBi2O4 nanorods might be advantageous to avoid the aggregation and control the leach out of metal ions. The calculated bandgap values of ~ 1.04, 1.02, and 0.94 eV were observed for CuBi2O4 with different amounts of Cu 1.0, 0.50, and 0.25 g, respectively. Varying the quantity of Cu metal ions easily tuned the bandgap value within the CuBi2O4-based nanorods. However, a further decrease in the bandgap value increased the recombination rate, and the less photocatalyst performance was observed. The CA degradation could be explained based on the species distribution. The CA pKa was mainly located between pKa1 and pKa2 of 4.43 and 8.6, respectively. The Cu within the CuBi2O4-based nanorods changed the electronic properties and the antibacterial ability. Therefore, the synthesized CuBi2O4-based nanorod cluster might be a promising material for the photocatalytic degradation of CA.

Strategic Doping Approach of the Fe-BiOI Microstructure: An Improved Photodegradation Efficiency of Tetracycline.

The present study describes the strategic doping of Fe metal ions into a BiOI microstructure using ex situ and in situ processes to synthesize a Fe-BiOI microstructure and their effect on photocatalytic degradation of tetracycline (TC). The data suggested that in situ Fe-BiOI (Fe-BiOI-In) has superior performance compared to ex situ Fe-BiOI (Fe-BiOI-Ex) due to the uniform dispersion of Fe within the Fe-BiOI material. Calculated bandgaps ∼1.8, ∼1.5, and 2.4 eV were observed for BiOI (without Fe), Fe-BiOI-In, and Fe-BiOI-Ex, respectively. Interestingly, Fe incorporation within BiOI might decrease the bandgap in Fe-BiOI-In due to the uniform distribution of metal ions, whereas increasing the bandgap in Fe-BiOI-Ex attributed to nonuniform distribution or agglomeration of metal ions. The uniform dispersion of Fe within Fe-BiOI modulates electronic properties as well as increases the exposure of Fe ions with TC, thereby higher degradation efficiency of TC. The in situ Fe-BiOI material shows 67 and 100% degradation of TC at 10 and 1 mg/L, respectively. The TC degradation was also found to be pH-dependent; when increasing the pH value up to 10, 94% degradation was achieved at 10 mg/L within 60 min of solar irradiation. The analysis was also performed over BiOI, which proves that Fe has a profound effect on TC degradation as Fe(II) tends to trigger oxidation-reduction by utilizing the chelate formation tendency of TC. Therefore, the prepared Fe-BiOI-In has the potential ability to degrade pharmaceutical compounds, especially, TC from wastewater.

Avoided crossings and dynamical tunneling close to excited-state quantum phase transitions.

Using the Wehrl entropy, we study the delocalization in phase space of energy eigenstates in the vicinity of avoided crossings in the Lipkin-Meshkov-Glick model. These avoided crossings, appearing at intermediate energies in a certain parameter region of the model, originate classically from pairs of trajectories lying in different phase-space regions which, contrary to the low-energy regime, are not connected by the discrete parity symmetry of the model. As coupling parameters are varied, a sudden increase of the Wehrl entropy is observed for eigenstates participating in avoided crossings that are close to the critical energy of the excited-state quantum phase transition. This allows us to detect when an avoided crossing is accompanied by a superposition of the pair of classical trajectories in the Husimi function of eigenstates. This superposition yields an enhancement of dynamical tunneling, which is observed by considering initial Bloch states that evolve partially into the partner region of the paired classical trajectories, thus breaking the quantum-classical correspondence in the evolution of observables.

The Medical Oncology resident mentor: situation and workload.

PURPOSE: The Spanish Society for Medical Oncology (SEOM, for its acronym in Spanish) and the National Commission for the Specialty of Medical Oncology seek to highlight the important workload and unrecognized dedication entailed in working as a Medical Oncology (MO) resident mentor, as well as its relevance for the quality of teaching units and the future of the specialty. MATERIALS AND METHODS: The current situation and opinion regarding the activity of MO resident mentors was analyzed by reviewing the standing national and autonomic community regulations and via an online survey targeting mentors, residents, and physicians who are not MO mentors. The project was supervised by a specially designated group that agreed on a proposal containing recommendations for improvement. RESULTS: Of the MO mentors, 90% stated that they did not have enough time to perform their mentoring duties. An estimated 172 h/year on average was dedicated to mentoring, which represents 10.1% of the total time. MO mentors dedicate an average of 6.9 h/month to these duties outside their workday. Forty-five percent of the mentors feel that their role is scantly recognized, if at all. CONCLUSIONS: The study reveals the substantial dedication and growing complexity of MO resident mentoring. A series of recommendations are issued to improve the conditions in which it is carried out, including the design of systems that adapt to the professional activity in those departments that have time set aside for mentoring tasks.

Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy.

PURPOSE: Elevated markers of host inflammation, a hallmark of cancer, have been associated with worse outcomes in several solid tumors. Here, we explore the prognostic role of the derived neutrophil-to-lymphocyte ratio (dNLR), across different tumor subtypes, in patients with early breast cancer. PATIENTS AND METHODS: This was a retrospective analysis of 1246 patients with lymph node-positive, operable early breast cancer enrolled in the GEICAM/9906 trial, a multicenter randomized phase 3 study evaluating adjuvant chemotherapy. dNLR was calculated as the ratio of neutrophils and the difference between total leukocytes and neutrophils in peripheral blood before chemotherapy. Disease-free survival (DFS) and overall survival were explored using a Cox proportional hazard analysis. RESULTS: The analysis comprised 1243 (99.8%) patients with dNLR data, with a median follow-up of 10 years. Data on intrinsic subtypes were available from 818 (66%) patients (luminal A 34%, luminal B 32%, HER2-enriched 21% and basal-like 9%). Median dNLR was 1.35 [interquartile range (IQR) 1.08-1.71]. In the whole population, dNLR was not prognostic after adjustment for clinico-pathological factors. However, dNLR ≥ 1.35 was independently associated with worse DFS in the hormone receptor-negative/HER2+ population (HR 2.86; p = 0.038) and in patients with one to three lymph node metastases (HR 1.32, p = 0.032). There was a non-significant association with worse DFS in non-luminal and in HER2-enriched tumors (HR 1.40, p = 0.085 and HR 1.53, p = 0.067). No significant interaction was observed between the treatment arm and dNLR. CONCLUSION: Elevated dNLR appears to be an adverse prognostic factor in hormone receptor-negative early breast cancer. TRIAL REGISTRATION: EudraCT: 2005-003108-12 (retrospectively registered 28/06/2005). ClinicalTrials.gov Identifier: NCT00129922 (retrospectively registered 10/08/2005). Results of this study were presented in part at the 2016 ESMO conference October 7-11, 2016, Copenhagen, Denmark (oral presentation).

Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists.

PURPOSE: The SEOM Future Plan is aimed at identifying the main challenges, trends and needs of the medical oncology speciality over the next years, including potential oncologist workforce shortages, and proposing recommendations to overcome them. METHODS: The estimations of the required medical oncologists workforce are based on an updated Medical Oncologist Register in Spain, Medical Oncology Departments activity data, dedication times and projected cancer incidence. Challenges, needs and future recommendations were drawn from an opinion survey and an advisory board. RESULTS: A shortage of 211 FTE medical oncologist specialists has been established. To maintain an optimal ratio of 158 new cases/FTE, medical oncology workforce should reach 1881 FTE by 2035. CONCLUSIONS: Main recommendations to face the growing demand and complexity of oncology services include a yearly growth of 2.5% of medical oncologist's workforce until 2035, and development and application of more accurate quality indicators for cancer care and health outcomes measure.

A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM).

PURPOSE: To converge on an expert opinion to define aggressive disease in patients with HER2-negative mBC using a modified Delphi methodology. METHODS: A panel of 21 breast cancer experts from the Spanish Society of Medical Oncology agreed upon a survey which comprised 47 questions that were grouped into three sections: relevance for defining aggressive disease, aggressive disease criteria and therapeutic goals. Answers were rated using a 9-point Likert scale of relevance or agreement. RESULTS: Among the 88 oncologists that were invited to participate, 81 answered the first round (92%), 70 answered the second round (80%), and 67 answered the third round (76%) of the survey. There was strong agreement regarding the fact that identifying patients with aggressive disease needs to be adequately addressed to help practitioners to decide the best treatment options for patients with HER2-negative mBC. The factors that were considered to be strongly relevant to classifying patients with aggressive HER2-negative mBC were a high tumor burden, a disease-free interval of less than 12-24 months after surgery, the presence of progressive disease during adjuvant or neoadjuvant chemotherapy and having a triple-negative phenotype. The main therapeutic goals were controlling symptoms, improving quality of life and increasing the time to progression and overall survival. CONCLUSIONS: High tumor burden, time to recurrence after prior therapy and having a triple-negative phenotype were the prognostic factors for which the greatest consensus was found for identifying patients with aggressive HER2-negative mBC. Identifying patients with aggressive disease leads to different therapeutic approaches.

SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016).

Chemotherapy-induced nausea and vomiting is one of the most worrisome adverse effects of chemotherapy for cancer patients. It can cause severe discomfort and affect the quality of life. In recent years, the incorporation of new drugs has increased the efficacy of antiemetic treatments in the control of emesis associated with chemotherapy. This guideline, in which we give some treatment recommendations with level of evidence and grade of recommendation, provides an update of the previously published guideline of the Spanish Society of Medical Oncology and represents our continued commitment to improving supportive care in cancer patients.

[Impact of Lean methodology to improve care processes and levels of satisfaction in patient care in a clinical laboratory]. / Impacto de la metodología Lean en la mejora de procesos asistenciales y niveles de satisfacción en la atención de pacientes en un laboratorio clínico.

INTRODUCTION: The application of the Lean methodology in health institutions is an effective tool to improve the capacity and workflow, as well as to increase the level of satisfaction of patients and employees. OBJECTIVE: To optimise the time of outpatient care in a clinical laboratory, by implementing a methodology based on the organisation of operational procedures to improve user satisfaction and reduce the number of complaints for delays in care. MATERIAL AND METHODS: A quasi-experimental before and after study was conducted between October 2011 to September 2012. XBar and S charts were used to observe the mean service times and standard deviation. The user satisfaction was assessed using service questionnaires. RESULTS: A reduction of 17 minutes was observed in the time of patient care from arrival to leaving the laboratory, and a decrease of 60% in complaints of delay in care. Despite the high staff turnover and 38% increase in the number of patients seen, a culture of empowerment and continuous improvement was acquired, as well as greater efficiency and productivity in the care process, which was reflected by maintaining standards 12 months after implementation. CONCLUSION: Lean is a viable methodology for clinical laboratory procedures, improving their efficiency and effectiveness.

SEOM clinical guidelines in early-stage breast cancer 2015.

Breast cancer is a major public health problem. Despite remarkable advances in early diagnosis and treatment, one in three women may have metastases since diagnosis. Better understanding of prognostic and predictive factors allows us to select the most appropriate adjuvant therapy in each patient. In these guidelines, we summarize current evidence for the medical management of early-stage breast cancer.

SEOM guidelines on hydroelectrolytic disorders.

Hydroelectrolytic disorders are one of the most common metabolic complications in cancer patients. Although often metabolic alterations affecting various ions are part of the manifestations of the oncological disease, even in the form of paraneoplastic syndrome, we must not forget that very often, these disorders could be caused by various drugs, including some of the antineoplastic agents most frequently used, such as platin derivatives or some biologics. These guidelines review major management of diagnosis, evaluation and treatment of the most common alterations of sodium, calcium, magnesium and potassium in cancer patients. Aside from life-sustaining treatments, we have reviewed the role of specific drug treatments aimed at correcting some of these disorders, such as intravenous bisphosphonates for hypercalcemia or V2 receptor antagonists in the management of syndrome of inappropriate antidiuretic hormone secretion-related hyponatremia.

CLASIFICACIÓN DE LATIDOS DE CONTRACCIÓN VENTRICULAR PREMATURA BASADOS EN MÉTODOS DE APRENDIZAJE NO SUPERVISADO / CLASSIFICATION OF PREMATURE VENTRICULAR CONTRACTION BEATS BASED ON UNSUPERVISED LEARNING METHODS / CLASSIFICAÇÃO DE PREMATUROS BATIDAS CONTRAÇÃO VENTRICULAR BASEADO SUPERVISIONADO MÉTODOS DE APRENDIZAGEM

Las enfermedades cardiovasculares son la principal causa de mortalidad en el mundo, por lo que el desarrollo de algoritmos que detecten arritmias cardíacas en tiempo real se ha convertido en un campo de investigación importante. El desarrollo de estos algoritmos ha conllevado a la mejora de dispositivos cardiacos portátiles. Este artículo presenta el desempeño de dos algoritmos basados en aprendizaje de máquina no supervisado para la detección de latidos de contracción ventricular prematura en la señal ECG. Los latidos se extraen de las bases de datos del MIT-BIH, los cuales fueron pre-procesados y segmentados por el grupo de investigación de Dinámica Cardiovascular de la UPB. La Transformada Wavelet Discreta, el Análisis de Componentes Principales y un método híbrido propuesto son implementados para la extracción de características y reducción de dimensiones, a partir de los cuales se generan 8 espacios de características para la evaluación de los algoritmos. Kmeans y Mapas auto-organizados son desarrollados y comparados en términos de precisión y costo computacional. Se logró una especificidad del 96.22 % y una sensibilidad del 95.04 % con un tiempo de ejecución de 79.41µs por latido. Los resultados permiten concluir que estos métodos pueden implementarse en aplicaciones de detección de arritmias en tiempo real debido a su bajo costo computacional.

Cardiovascular diseases are the principal cause of mortality in the world, so that the development of algorithms that detect cardiac arrhythmias in real time has become an important field of research. The development of these algorithms has led to the improvement of wearable cardiac devices. This paper presents the performance of two algorithms based in unsupervised learning methods for the detection of Premature Ventricular Contraction in the ECG signal. The beats are extracted from MIT-BIH databases, which were preprocessed and segmented by the UPB’s Dynamic Cardiovascular research group. The Discrete Wavelet Transform (DWT), Principal Component Analysis (PCA) and a proposed hybrid method are implemented for the feature extraction and dimension reduction, from which 8 feature spaces are generated and tested. Kmeans and Self Organizing Maps are developed and compared in terms of accuracy and computational cost. Specificity of 96.22 % and sensitivity of 95.94% with 79.41µs per beat are accomplished. The results show that these methods can be implemented in applications of real time arrhythmia detection because of their low computational cost.

A doença cardiovascular é a principal causa de morte em todo o mundo, de modo que o desenvolvimento de algoritmos para detectar arritmias cardíacas, em tempo real, tornou-se um importante campo de pesquisa. O desenvolvimento desses algoritmos tem levado a melhores dispositivos cardíacos portáteis. Este artigo apresenta o desempenho dos dois com base na aprendizagem de máquina sem supervisão para detecção de batidas de contração ventriculares prematuras nos algoritmos de sinais de ECG. As batidas são extraídos das bases de dados do MIT-BIH, que foram pré-processados e segmentado pelo grupo da UPB Cardiovasculares Dynamics pesquisa. A Transformada Wavelet Discreta, Análise de Componentes Principais e uma abordagem híbrida proposta são implementadas para extração de características e redução de dimensão, a partir do qual 8 espaços de recursos para a avaliação dos algoritmos são gerados. Kmeans e mapas de auto-organização são desenvolvidos e comparados em termos de precisão e custo computacional. A especificidade de 96,22% e uma sensibilidade de 95,04% com um tempo de execução de 79.41µs por batida foi alcançado. Os resultados mostram que estes métodos podem ser implementados em aplicações de detecção de arritmia em tempo real, devido ao seu baixo custo computacional.

Even apparently insignificant chemical deviations among bioequivalent generic antibiotics can lead to therapeutic nonequivalence: the case of meropenem.

Several studies with animal models have demonstrated that bioequivalence of generic products of antibiotics like vancomycin, as currently defined, do not guarantee therapeutic equivalence. However, the amounts and characteristics of impurities and degradation products in these formulations do not violate the requirements of the U.S. Pharmacopeia (USP). Here, we provide experimental data with three generic products of meropenem that help in understanding how these apparently insignificant chemical differences affect the in vivo efficacy. Meropenem generics were compared with the innovator in vitro by microbiological assay, susceptibility testing, and liquid chromatography/mass spectrometry (LC/MS) analysis and in vivo with the neutropenic guinea pig soleus infection model (Pseudomonas aeruginosa) and the neutropenic mouse thigh (P. aeruginosa), brain (P. aeruginosa), and lung (Klebisella pneumoniae) infection models, adding the dihydropeptidase I (DHP-I) inhibitor cilastatin in different proportions to the carbapenem. We found that the concentration and potency of the active pharmaceutical ingredient, in vitro susceptibility testing, and mouse pharmacokinetics were identical for all products; however, two generics differed significantly from the innovator in the guinea pig and mouse models, while the third generic was therapeutically equivalent under all conditions. Trisodium adducts in a bioequivalent generic made it more susceptible to DHP-I hydrolysis and less stable at room temperature, explaining its therapeutic nonequivalence. We conclude that the therapeutic nonequivalence of generic products of meropenem is due to greater susceptibility to DHP-I hydrolysis. These failing generics are compliant with USP requirements and would remain undetectable under current regulations.